ABSTRACT
Background SARS-CoV-2 causes significant morbidity and mortality in health care settings. Our understanding of the distribution of this virus in the built healthcare environment and wastewater, and relationship to disease burden, is limited.
Methods We performed a prospective multi-center study of environmental sampling of SARS-CoV-2 from hospital surfaces and wastewater and evaluated their relationships with regional and hospital COVID-19 burden. We developed and validated a qPCR-based approach to surface sampling, and swab samples were collected weekly from different locations and surfaces across two tertiary care hospital campuses for a 10-week period during the pandemic, along with wastewater samples.
Results Over a 10-week period, 963 swab samples were collected and analyzed. We found 61 (6%) swabs positive for SARS-CoV-2, with the majority of these (n=51) originating from floor samples. Wards that actively managed patients with COVID-19 had the highest frequency of positive samples (p<0.01). Detection frequency in built environment swabs was significantly associated with active cases in the hospital throughout the study (p<0.025). Wastewater viral signal changes appeared to predate change in case burden.
Conclusions Environment sampling for SARS-CoV-2, in particular from floors, may offer a unique and resolved approach to surveillance of COVID-19.
Competing Interest Statement
Author ED works for DNA Genotek which provided sampling swabs in-kind for this study in an unrestricted fashion. DNA Genotek had no control over the findings, interpretations, or conclusions published in this paper. All other authors have no relevant conflicts to disclose.
Funding Statement
This work was supported by TOHAMO (The Ottawa Hospital Academic Medical Organization), Alliance Grant # 554478 - 20 from the Natural Sciences and Engineering Research Council (NSERC), Carleton University Rapid Response Research Grant, and the Jarislowsky Foundation. DNA Genotek provided sampling swabs in-kind for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research ethics board approval was obtained through the Ottawa Health Science Network Research Ethics Board (OHSN-REB) for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Co-PIs
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
